Equities researchers at Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a research note issued on Wednesday, Marketbeat Ratings reports. The firm set an “overweight” rating on the stock.
Palvella Therapeutics Trading Up 1.8 %
Shares of PVLA stock opened at $12.00 on Wednesday. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.
Insider Buying and Selling at Palvella Therapeutics
In other news, Director George M. Jenkins bought 4,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the acquisition, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Micron Stock Under $100: Seize the AI-Driven Upside
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- 3 Tickers Leading a Meme Stock Revival
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
